NCT03246880View on ClinicalTrials.gov

Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

455

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Tamsulosin 0.2mg

per oral for 12weeks after 2\~4weeks run-in period

DRUG

Tadalafil 5mg

per oral for 12weeks after 2\~4weeks run-in period

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY